For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
HealthDay on MSN2d
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate CancerFor patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...
Patient characteristics and survival in primary prostate sarcomas: An analysis of the SEER database.
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 ...
Pfizer Inc. announced positive results from the phase 3 TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an ...
Common Sense Oncology Outlines 9 Core Trial Principles Leaders of the Common Sense Oncology initiative, launched 1.5 years ago as “a new patient-centered movement in cancer care,” outline ...
Today, Pfizer said that its phase 3 TALAPRO 2 trial of PARP drug Talzenna (talazoparib) in combination with its Astellas-partnered anti-androgen therapy Xtandi (enzalutamide) reduced radiographic ...
Analysts think a stronger challenge to Lynparza in first-line mCRPC could come from another PARP drug, Pfizer’s Talzenna (talazoparib) combined with Xtandi (enzalutamide), which reported new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback